Focus-X Therapeutics, a nuclide drug company that was invested in and incubated by Viva Biotech, successfully reached an acquisition agreement with Full-Life Technologies. Under the terms of the acquisition, Full-Life will acquire Focus-X for US$245 ...
Rocket Pharmaceuticals, a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet needs, has announced that it has completed the previously announced acquisition of ...
AstraZeneca has announced an agreement to acquire Neogene Therapeutics, a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting ...
Popular Posts
